Kuros Biosciences AG (SWX:KURN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
30.64
-0.38 (-1.23%)
At close: Dec 5, 2025
56.65%
Market Cap 1.20B
Revenue (ttm) 103.35M
Net Income (ttm) -6.07M
Shares Out 39.15M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE 103.86
Dividend n/a
Ex-Dividend Date n/a
Volume 68,378
Average Volume 144,332
Open 31.14
Previous Close 31.02
Day's Range 30.48 - 31.32
52-Week Range 14.00 - 34.20
Beta 0.67
RSI 58.16
Earnings Date Mar 10, 2026

About Kuros Biosciences AG

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bon... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2016
Employees 122
Stock Exchange SIX Swiss Exchange
Ticker Symbol KURN
Full Company Profile

Financial Performance

In 2024, Kuros Biosciences AG's revenue was 75.56 million, an increase of 125.11% compared to the previous year's 33.56 million. Losses were -4.29 million, -68.75% less than in 2023.

Financial Statements

News

Kuros 9-month Revenue Up 77%; Raises 2025 Sales Guidance

(RTTNews) - Kuros Biosciences (KURN.SW) reported that, for the first nine months of 2025, total group revenue was $101.1 million, up by 77% compared with the same period in 2024. Revenue from Direct M...

7 weeks ago - Nasdaq